Mengli Xu1, Xiangrui Meng1, Yao Lu1, Feng Wang1. 1. Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Abstract
Background: Trastuzumab plus chemotherapy is the standard-of-care (SoC) first-line therapy for HER2-positive advanced gastric cancer. Combining PD-1 antibody with SoC first-line therapy showed encouraging results in the KEYNOTE-811 study. The retrospective study aims to evaluate the efficacy and safety of SoC vs. SoC plus camrelizumab (PD-1 antibody) as a first-line treatment for HER2-positive advanced gastric cancer in a real-world setting. Methods: This study included 41 patients with HER2-positive advanced gastric cancer who received SoC or SoC plus camrelizumab from June 2017 to December 2020. The endpoints were objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. Results: Thirteen patients received SoC (SoC group) and 28 patients received SoC plus camrelizumab (camrelizumab group). As of December 2020, the median follow-up time was 10.0 months. In the camrelizumab and SoC groups, the ORRs were 75.0% and 46.2% (P=0.032), respectively. The DCR was 96.4% in the camrelizumab group and 69.2% in the SoC group (P=0.003). The median OS was 18.4 in the camrelizumab group and 13.2 months in the SoC group [hazard ratio (HR) =0.343; 95% confidence interval (CI): 0.151-0.783; P=0.008]. The median PFS was 3.78 in the camrelizumab group and 1.74 months in the SoC group (HR =0.416; 95% CI: 0.186-0.932; P=0.027). In the HER2 subgroups in the camrelizumab group, the median PFS of immunohistochemistry (IHC) 3+ vs. IHC 2+ fluorescence in situ hybridization (FISH) was 11.3 vs. 9.0 months (HR =1.684; 95% CI: 0.710-3.994; P=0.047). The incidence rates of reactive cutaneous capillary endothelial proliferation (RCCEP) (P<0.001), abnormal liver function (P=0.040), and hypothyroidism (P=0.039) between the two groups were significantly different. RCCEP and hypothyroidism were considered to be related to camrelizumab. Conclusions: First-line treatment with camrelizumab combined with SoC showed significant clinical benefits and good tolerance compared with SoC for HER2-positive advanced gastric cancer. 2022 Journal of Gastrointestinal Oncology. All rights reserved.
Background: Trastuzumab plus chemotherapy is the standard-of-care (SoC) first-line therapy for HER2-positive advanced gastric cancer. Combining PD-1 antibody with SoC first-line therapy showed encouraging results in the KEYNOTE-811 study. The retrospective study aims to evaluate the efficacy and safety of SoC vs. SoC plus camrelizumab (PD-1 antibody) as a first-line treatment for HER2-positive advanced gastric cancer in a real-world setting. Methods: This study included 41 patients with HER2-positive advanced gastric cancer who received SoC or SoC plus camrelizumab from June 2017 to December 2020. The endpoints were objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. Results: Thirteen patients received SoC (SoC group) and 28 patients received SoC plus camrelizumab (camrelizumab group). As of December 2020, the median follow-up time was 10.0 months. In the camrelizumab and SoC groups, the ORRs were 75.0% and 46.2% (P=0.032), respectively. The DCR was 96.4% in the camrelizumab group and 69.2% in the SoC group (P=0.003). The median OS was 18.4 in the camrelizumab group and 13.2 months in the SoC group [hazard ratio (HR) =0.343; 95% confidence interval (CI): 0.151-0.783; P=0.008]. The median PFS was 3.78 in the camrelizumab group and 1.74 months in the SoC group (HR =0.416; 95% CI: 0.186-0.932; P=0.027). In the HER2 subgroups in the camrelizumab group, the median PFS of immunohistochemistry (IHC) 3+ vs. IHC 2+ fluorescence in situ hybridization (FISH) was 11.3 vs. 9.0 months (HR =1.684; 95% CI: 0.710-3.994; P=0.047). The incidence rates of reactive cutaneous capillary endothelial proliferation (RCCEP) (P<0.001), abnormal liver function (P=0.040), and hypothyroidism (P=0.039) between the two groups were significantly different. RCCEP and hypothyroidism were considered to be related to camrelizumab. Conclusions: First-line treatment with camrelizumab combined with SoC showed significant clinical benefits and good tolerance compared with SoC for HER2-positive advanced gastric cancer. 2022 Journal of Gastrointestinal Oncology. All rights reserved.
Authors: Clare Taylor; Dawn Hershman; Nina Shah; Nicole Suciu-Foca; Dan P Petrylak; Robert Taub; Linda Vahdat; Bin Cheng; Mark Pegram; Keith L Knutson; Raphael Clynes Journal: Clin Cancer Res Date: 2007-09-01 Impact factor: 12.531
Authors: Bharat K R Chaganty; Songbo Qiu; Anneliese Gest; Yang Lu; Cristina Ivan; George A Calin; Louis M Weiner; Zhen Fan Journal: Cancer Lett Date: 2018-05-08 Impact factor: 8.679
Authors: Kohei Shitara; Eric Van Cutsem; Yung-Jue Bang; Charles Fuchs; Lucjan Wyrwicz; Keun-Wook Lee; Iveta Kudaba; Marcelo Garrido; Hyun Cheol Chung; Jeeyun Lee; Hugo Raul Castro; Wasat Mansoor; Maria Ignez Braghiroli; Nina Karaseva; Christian Caglevic; Luis Villanueva; Eray Goekkurt; Hironaga Satake; Peter Enzinger; Maria Alsina; Al Benson; Joseph Chao; Andrew H Ko; Zev A Wainberg; Uma Kher; Sukrut Shah; S Peter Kang; Josep Tabernero Journal: JAMA Oncol Date: 2020-10-01 Impact factor: 31.777